By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
Business

Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

NeoStem (AMEX:NBS) announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line from the Chinese State Food and Drug Administration (SFDA).

NeoStem (AMEX:NBS) announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line from the Chinese State Food and Drug Administration (SFDA).

NeoStem, a pharmaceutical company that focuses on stem cell-based technologies, acquired a 51% interest in China-based Suzhou Eyre, which manufactures and develops generic antibiotics and anti-infective drugs, from China Biopharmaceutical Holdings in October 2009.

The sixth line of production, of which there are two more awaiting approval, will push Suzhou Eyre’s product count to nearly 200 drugs. The line is responsible for 20 finished pharmaceutical products, 80% of which are on the China National Insurance Drug List.

More Read

Interview with Paul Tunnah Founder of Pharmaphorum
CMS Proposed Payment Changes for Outpatient Procedures
Bad Blood: Orthopedic Surgeons vs. Hospitals
HCP Use of Social Media for Recruitment [INFOGRAPHIC]
OIG Clears the Path for Physician Incentives

The company’s production lines provided 99% of its $70 million sales in 2010. Its first quarter sales for this year totaled $18 million, a 15% year-over-year increase.

“The Chinese pharmaceutical market, which is the third largest in the world, has estimated sales of over $50 billion for 2011, and is expected to double in the next five years,” said NeoStem CEO Dr. Robin Smith.

According to recent analyst reports, NeoStem, with the assistance of Suzhou Eyre, could see a revenue growth rate of 20% between 2011 and 2013, with the potential to reach $119 million in pharmaceutical sales by 2013.

Indeed, Suzhou Eyre is also in the midst of re-locating to its new 53,000 square foot facility, which it expects will loosen its capacity constraints, improve its productivity and double its capacity.

“Based on the capacity of the new facility, and anticipated volume growth, Erye’s top line revenues should see solid growth in the years ahead and NeoStem’s management will consider our multiple options to realizing the benefits of this increasingly valuable asset,” Smith added.

Aside from its Chinese pharma business, New York-based Neostem has gradually expanded its operations since starting out as a provider of adult stem cell collection and storage services, branching out into cell therapeutics, which is focused on using stem cells to help cure disease.

In January, the company acquired Progenitor, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US.

Progenitor has performed over 30,000 cell therapy procedures and has processed and stored over 18,000 cell therapy products.

As a result of the acquisition, NeoStem can also now develop stem cell therapies in-house, placing it in a solid position for future growth in the field.

With positive results coming out of China today, NeoStem’s stock jumped almost 5% on the AMEX on Monday, trading at $1.47 per share. –Olivia D’Orazio

Source

 

TAGGED:chinahealthcare business
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

medical marketing strategy
BusinessMedical DevicesTechnology

Medical Device DTC Marketing: Digital Co-Marketing and the Power of the Referral (Part 3 of 4)

July 22, 2014

Trusted Source: Certified Medical Apps and Products

April 20, 2012

Nursing Pays

December 31, 2011

Medical Imaging March Madness – Stage 2 and the Health Affairs IT Study Debate

March 28, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?